Cargando…
MON-608 Incidence And Onset Of Thyroid Dysfunction In Patients Treated With Pd-1 Inhibitors At A Medical Center
Background: The programmed cell death-1 (PD-1) pathway is a novel therapeutic target in immune checkpoint therapy for cancer. Pembrolizumab and Nivolumab are anti-PD-1 monoclonal antibodies. Thyroid dysfunction is a known adverse effect of these drugs, but there is limited data on incidence.(1,2) Ou...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Endocrine Society
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6550566/ http://dx.doi.org/10.1210/js.2019-MON-608 |